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Abstract Myelinating oligodendrocytes are essential for central nervous system (CNS) formation
and function. Their disruption is implicated in numerous neurodevelopmental, neuropsychiatric and
neurodegenerative disorders. However, recent studies have indicated that oligodendrocytes may
be tractable for treatment of disease. In recent years, zebrafish have become well established for
the study of myelinating oligodendrocyte biology and drug discovery in vivo. Here, by automating
the delivery of zebrafish larvae to a spinning disk confocal microscope, we were able to automate
high-resolution imaging of myelinating oligodendrocytes in vivo. From there, we developed an
image analysis pipeline that facilitated a screen of compounds with epigenetic and post-
translational targets for their effects on regulating myelinating oligodendrocyte number. This
screen identified novel compounds that strongly promote myelinating oligodendrocyte formation
in vivo. Our imaging platform and analysis pipeline is flexible and can be employed for high-
resolution imaging-based screens of broad interest using zebrafish.
DOI: https://doi.org/10.7554/eLife.35136.001
Introduction
Myelin is a lipid-rich structure made by specialised glial cells, oligodendrocytes in the central nervous
system (CNS) and Schwann cells in the peripheral nervous system (PNS), that facilitates the rapid
propagation of nerve impulses and provides trophic and metabolic support to axons (Nave and
Werner, 2014). In mammals, myelination in the CNS starts around birth and continues well into adult
life (Yeung et al., 2014). New myelin is thought to be generated by a combination of the differentia-
tion of new oligodendrocytes (Hill et al., 2018; Hughes et al., 2018; Young et al., 2013) and
remodelling of existing myelin (Auer et al., 2018; Snaidero et al., 2014). New oligodendrocytes
can be produced throughout life by tissue-resident oligodendrocyte progenitor cells (OPCs), which
represent about 5% of CNS cells life-long (Dawson et al., 2003), and to a lesser extent by neural
stem cell-derived OPCs (Samanta et al., 2015). There is increasing evidence that myelination is con-
trolled by neuronal activity, and that regulation of myelin is important for both nervous system health
and functional plasticity (Almeida and Lyons, 2017). Indeed, loss of myelin in late adulthood corre-
lates with age-related cognitive decline (Deary et al., 2006; Lu et al., 2013; Penke et al., 2010).
Reflecting its fundamental importance, it is increasingly clear that disruption to myelin and myelinat-
ing glia contributes to numerous diseases of the nervous system, including neuropathies of the PNS
and a variety of conditions of the CNS. These include: neonatal hypoxia (Buser et al., 2012); child-
hood leukodystrophies (Boespflug-Tanguy et al., 2008); neurodevelopmental disorders including
autism (Pacey et al., 2013) and schizophrenia (Hercher et al., 2014); as well as neurodegenerative
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conditions including multiple sclerosis (MS) (Compston and Coles, 2008), motor neuron disease
(Kang et al., 2013), Huntington’s disease (Huang et al., 2015) and Alzheimer’s disease (Bartzo-
kis, 2011). Furthermore, disruption to oligodendrocytes and myelin play important roles in the path-
ogenesis of glioma (Venkatesh et al., 2015) and white-matter stroke (Matute et al., 2013).
However, it is now clear that OPCs and neural stem cells present in the CNS throughout life can gen-
erate new oligodendrocytes following damage to myelin, and that these cells can in turn regenerate
myelin through the process of remyelination (Franklin and ffrench-Constant, 2017; Prineas and
Connell, 1979; Samanta et al., 2015; Zawadzka et al., 2010). This capacity to generate myelin
throughout life, including in response to damage, raises hope that the oligodendrocyte lineage may
be tractable for the treatment of disease.
Depending on the specific disease, multiple bottlenecks can limit the normal formation or regen-
eration of myelinating oligodendrocytes, including disruption to OPC specification, proliferation,
migration, oligodendrocyte differentiation or (re)myelination, reviewed by (Cole et al., 2017). For
example, in MS, while certain areas with demyelinated axons completely lack OPCs, others have
plentiful OPCs that do not differentiate into oligodendrocytes (Boyd et al., 2013; Chang et al.,
2000; Kuhlmann et al., 2008; Lucchinetti et al., 1999). Even when oligodendrocytes differentiate
and regenerate myelin, new myelin sheaths are characterised by being shorter and thinner than nor-
mal (Franklin and ffrench-Constant, 2017; Prineas and Connell, 1979). The fact that many demyeli-
nated lesions contain OPCs that do not differentiate has prompted efforts to identify strategies to
promote oligodendrocyte differentiation. Indeed, recent unbiased phenotypic screens have led to
the identification of several hit compounds that promote oligodendrocyte differentiation in vitro
(Deshmukh et al., 2013; Joubert et al., 2010; Mei et al., 2014; Mei et al., 2016; Najm et al.,
2015; Peppard et al., 2015; Porcu et al., 2015). A number of these hits have been validated in vivo
(Cole et al., 2017), and one, clemastine, has even shown efficacy in improving optic nerve function
in patients with MS (Green et al., 2017). This remarkable progress highlights the power of discovery
screens, and indicates that the oligodendrocyte lineage is therapeutically tractable for the treatment
of disease. However, there remains a great need to identify safe, effective, and specific compounds
capable of regulating distinct stages of the oligodendrocyte lineage, from specification through to
(re)myelination.
In recent years zebrafish have become well established for the study of oligodendrocyte biology
and myelination in vivo, reviewed in (Czopka, 2016). Phenotypic gene discovery screens have identi-
fied novel factors required for myelination (for example Kearns et al., 2015; Lyons et al., 2009),
and live imaging based studies have provided insight into cellular mechanisms of oligodendrocyte
development and myelination (for example Almeida et al., 2011; Auer et al., 2018; Czopka et al.,
2013; Kirby et al., 2006; Snaidero et al., 2014). Zebrafish are now also widely used for chemical
biology and drug discovery, due to their conservation of molecular and cellular function with mam-
mals and natural properties that make them ideal for scalable and efficient compound-based in vivo
screens. Zebrafish embryos can be generated in very large numbers and their externally fertilised
eggs develop rapidly from a single cell to a freely swimming, optically transparent animal with exten-
sive myelination in just a few days, meaning entire developmental events and biological processes
can be observed in real time (for example Keller et al., 2008). Compounds can be taken up by the
embryo following direct addition to the water, and phenotypic screens can be carried out either by
direct assessment of organ formation, cardiovascular function, general development or behaviour,
or using a variety of cell-type and tissue specific markers and reporters (for example Milan et al.,
2003; North et al., 2007; Peterson et al., 2000, 2004; Rihel et al., 2010). Since the first ground-
breaking phenotypic chemical screen using zebrafish in 2000 (Peterson et al., 2000), numerous
others have followed (Rennekamp and Peterson, 2015), including assessment of oligodendrocyte
lineage formation (Buckley et al., 2010) and a number that have led to new clinical trials
(MacRae and Peterson, 2015; North et al., 2007; Yu et al., 2008). Using an in vivo system is partic-
ularly advantageous for screening complex biological processes, such as myelination, that are diffi-
cult to fully recapitulate in vitro (Buckley et al., 2008), and recent advances in automated embryo
handling technologies have made scalable in vivo screens using zebrafish feasible (Chang et al.,
2012; Pardo-Martin et al., 2010; Wang et al., 2015). Here we combine a commercially available
platform that automates the delivery of zebrafish from multi-well plates to a microscope platform,
with a customised spinning disk confocal microscope to automate high-resolution image acquisition.
We develop an image handling and analysis pipeline that allowed us to execute an automated
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screen which identified several novel hit compounds that regulate myelinating oligodendrocyte num-
ber. In addition, we expect our imaging and analysis capacities to be broadly useful to researchers
interested in executing scalable, high-resolution in vivo analyses of diverse biological processes in
zebrafish.
Results
Automated imaging of zebrafish larvae at high resolution
In order to establish an automated high-resolution in vivo screening platform for zebrafish, we
decided to couple the Large Particle (LP) Sampler and the VAST BioImager (Pardo-Martin et al.,
2010) (both Union Biometrica, Holliston, MA) with a customised spinning disk confocal microscope
(Carl Zeiss Microscopy GmbH, Jena, Germany), which together we refer to as VAST-SDCM. The LP
Sampler automates the delivery of zebrafish larvae from the wells of a multi-well plate to the VAST
BioImager platform (Chang et al., 2012). Core to the VAST BioImager is a thin-walled glass capillary
(10 mm thick glass) in which zebrafish can be imaged (Figure 1A–C). The capillary can be rotated
fully (360 degrees) around the x-axis (Figure 1C,D; Video 1), such that animals can be automatically
oriented according to user-defined templates (Pardo-Martin et al., 2010). We decided to use a
spinning disk confocal system for image acquisition, because of the balance of high-speed and high-
resolution imaging capacity with the flexibility to customise the configuration on a standard upright
microscope (see Materials and methods). The VAST BioImager can accommodate glass capillaries of
600–750 mm internal diameter, which allows imaging of zebrafish embryos and young larvae
(Figure 1C,D).
Table 1 provides an overview of image acquisition parameters and performance outputs, includ-
ing acquisition speeds, resolution, and general throughput of the VAST-SDCM. In initial tests using
our transgenic reporter of myelinating oligodendrocytes, Tg(mbp:EGFP), we found that we could
image all of the myelinating glial cells in a zebrafish larva at 4 days post fertilisation (dpf), with a suc-
cess rate of 83%, in approximately 60 s, using a 10X objective (849 nm pixel size) (Figure 1E,F and
Video 2). In addition, we imaged Tg(mbp:EGFP-CAAX) larvae, in which EGFP is membrane local-
ised, and therefore enriched in myelin, using a 20X objective (141 nm pixel size), highlighting the
potential of the system for higher resolution imaging (Figure 1G).
Given the performance obtained in our initial studies, we reasoned that the VAST-SDCM platform
could provide the speed and resolution required for scalable imaging-based screens of myelinating
oligodendrocyte development in vivo.
Image handling: selection of regions of interest
We first wanted to identify a region of the CNS that might be suited to an automated imaging-
based screen. Myelinating oligodendrocytes differentiate in the zebrafish spinal cord from around 2
dpf, first in the ventral area and soon thereafter in the dorsal area, with significant numbers present
by 4 dpf (Figure 1E,F). Due to their sparse distribution, we found that myelinating oligodendrocyte
number in the dorsal spinal cord could be reliably assessed by compressing 3D z-stacks into 2D max-
imum intensity projections (MIPs): manual counts of cells in 2D MIPs average 33.3 vs 3D stereological
counts of 35.4 (Student’s t-test, p=0.61, Figure 2—figure supplement 1). To develop an automated
method to quantify myelinating oligodendrocyte number in this region, we first needed a method to
automatically select the dorsal spinal cord as a specific region of interest (ROI) in 2D MIPs. We
applied a landmark-based segmentation approach to achieve this. The early myelination of the ven-
tral spinal cord is reflected by high-intensity fluorescent reporter expression in Tg(mbp:EGFP) ani-
mals. This allowed us to automatically plot points of peak fluorescence in the X-Y plane of tiled 2D
MIPs and draw a line between points and thus delineate myelinating oligodendrocytes of the ventral
spinal cord (Figure 2A–E, Video 3). From this defined line, we plotted the distance to the dorsal-
most cells in the spinal cord, which allowed us to demarcate the dorsal spinal cord as a specific area
of interest (Figure 2F,G). Our image analysis script also allows users to manually adjust any occa-
sional errors that may occur in defining the line demarcating the ventral spinal cord (referred to as
‘Refined ROIs’). However, following the fully automated ROI specification process in 196 animals, we
counted on average only 1.2 cells per animal outwith the automatically assigned ROIs (Figure 2—fig-
ure supplement 2). Therefore, we reasoned that we could use our 2D landmark-based segmentation
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Figure 1. VAST-SDCM setup for rapid, automated image acquisition at subcellular resolution. (A) Overview of custom VAST BioImager and spinning-
disk microscope setup, highlighting key components. (B) Schematic representation of hardware interaction between Zeiss SDCM, VAST BioImager and
LP Sampler. (C) Representative brightfield image produced by VAST BioImager, showing a 4 dpf zebrafish embryo in a 600 mm glass capillary. (D)
Illustration of relative setup of microscope objective and capillary. Note that the piezo range (400 mm) requires for two stacks (blue and magenta) to be
acquired per tile of fish (6-tiles with 10% overlap required to image entire 4 dpf larva). (E) Maximum intensity projection of images of Tg(mbp:EGFP)
zebrafish, following tiled merging of 6 z-stacks. Scale bar = 200 mm. (F) and G) Example images of mid-trunk region of Tg(mbp:EGFP) and Tg(mbp:
Figure 1 continued on next page
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process to work towards a fully automated screen to identify compounds that regulate myelinating
oligodendrocyte number in the dorsal spinal cord. Whilst in this case we were able to successfully
quantify our cells of interest in 2D MIPs, this is not always the case. As such, further to the above
tools, we provide a method for selecting a 3D sub-region from an image dataset (3D_Crop_v1.1.ijm,
see Materials and methods, Figure 2—figure supplement 3A–C, Video 4, and Early, 2018), or
alternatively, a plugin for recording the depth of maximum intensity for a given xy location in a 3D
dataset (D_Projector_v1.1.jar, see Materials and methods, Figure 2—figure supplement 3D and
Early, 2018). These allow for either removal of unwanted/non-specific fluorescence, or recording of
3D spatial information, and could be combined with the scripts presented herein.
Automated quantification of oligodendrocyte cell number
Having established a method to automatically demarcate the dorsal spinal cord as a specific ROI, we
next tested the ability of an available 2D maxima identification tool (ImageJ’s inbuilt findMaxima
function) to identify cells in this region. To remove false positive maxima that do not resemble cells,
we included an additional processing step called processCells, which can be used to assess cell size,
shape and fluorophore expression (Figure 3 and see Materials and methods). These functions were
applied within the automatically identified dorsal ROI, and accurately quantified cell number com-
pared to manual assessment (Figure 3 and see Materials and methods). Our image handling script
also saves the selections made by the findMaxima and processCells functions for posthoc validation
and further analyses. For example, in circumstances where one may wish to manually confirm accu-
racy of cell counts, our script also allows for manual refinement of assignments (Figure 3). Manual
refinement does come with a significant cost in investigator time. For example, the completely auto-
mated process can process an individual sample in under a second and the 288 animals in a 96 well
plate in 3.5 min. In contrast manual refinement takes an average of 50 s per sample to process, and
circa 4 hr per plate. Nonetheless this is still significantly less time than it takes for an expert to assess
cell number in the dorsal spinal cord of 288 animals from 3D stacks (circa 34 hr). In summary, the
combination of automated ROI specification and automated cell counting indicated that we could,
in principle, execute a fully automated image acquisition and analysis screen for compounds that
regulate oligodendrocyte development using the VAST-SDCM (Video 5).
Validation of automated analysis to identify changes in myelinating
oligodendrocyte number
Following a manual screen to identify compounds that regulated myelination, using our Tg(mbp:
EGFP-CAAX) reporter, we identified the compound SKP2-C25 as promoting myelination. In this
manual screen we treated embryos with compounds from 2 to 4 dpf and assessed myelination at 4
dpf. Follow-up analyses showed that SKP2-C25 increased myelination, as assessed by electron
microscopy, and did so by increasing oligodendrocyte number (Almeida et al., 2018). SKP2-C25 is
reported to be a selective inhibitor of the Skp2 SCF ubiquitin ligase complex that contributes to the
ubiquitin-directed proteasomal degradation of proteins (Chan et al., 2013). To exemplify the power
of zebrafish to define how compounds affect spe-
cific stages of oligodendrocyte lineage progres-
sion, we show here, using time-lapse microscopy
that treatment of animals with SKP2-C25
increases the proliferation of OPCs between 2
and 3 dpf (Figure 4—figure supplement 1 and
Video 6). We have previously shown that oligo-
dendrocytes differentiate by default in zebrafish
to mediate the early myelination observed in the
larval spinal cord (Almeida et al., 2018).
Figure 1 continued
EGFP-CAAX) fish imaged with 10  0.5 NA (3  3 binning) and 20  1 NA (1  1 binning) objectives respectively. Scale bars = 50 and 25 mm
respectively). dSC = dorsal spinal cord, vSC = ventral spinal cord and pLL = posterior lateral line.
DOI: https://doi.org/10.7554/eLife.35136.002
Video 1. Movie of 4 dpf zebrafish larva in the VAST
BioImager capillary, showing the x-axis 360˚ rotational
capacity. Refers to Figure 1.
DOI: https://doi.org/10.7554/eLife.35136.003
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Therefore, upon an increase of OPC proliferation following SKP2-C25 treatment, there is a larger
pool of OPCs that differentiate by default, leading to the observed increase in myelinating
oligodendrocytes.
Given that SKP2-C25 increased myelinating oligodendrocyte number, we decided to use this
compound to assess the sensitivity of our automated imaging and analysis pipeline to detect rela-
tively subtle changes in oligodendrocyte number. We imaged control animals and those treated with
a range of concentrations of SKP2-C25 using the VAST-SDCM, and found that our imaging and anal-
ysis pipeline was indeed able to detect increases in myelinating oligodendrocyte number (Figure 4).
Therefore, we reasoned that our imaging and analysis pipeline had the sensitivity to detect changes
in myelinating oligodendrocyte cell number and thus could be employed to execute a fully auto-
mated screen.
Chemical screen for compounds that regulate myelinating
oligodendrocyte number
Having established a robust automated method for quantifying oligodendrocyte number in vivo, we
next wanted to carry out a screen for regulators of myelinating oligodendrocyte formation. For this,
we collated a small focused library of 175 compounds from three commercial sources (146 distinct
molecular entities) that targeted enzymes implicated in epigenetic and post-translational modifica-
tions, given the known importance of epigenetic mechanisms during oligodendrocyte development
(Copray et al., 2009; Liu et al., 2016). We rea-
soned that using a library with such diverse tar-
gets would allow us to identify compounds
affecting distinct stages of oligodendrocyte line-
age progression from OPC specification through
to differentiation and myelination. To ensure that
our screen would detect relatively subtle changes
in oligodendrocyte number, we calculated that
the sample size needed to detect the increase in
cell number seen for SKP2-C25 with 95% power
and p<0.05 significance values was 9 (see Materi-
als and methods). To account for potential auto-
mation errors (our initial data indicated an 83%
success rate for accurate loading, plus subse-
quent positioning and imaging), the number of
animals plated for analysis was increased to 12.
Prior to our imaging-based screen, we first car-
ried out an assessment of compound toxicity by
treating animals from 2 to 5 dpf with all com-
pounds at 100 mM, 10 mM and 1 mM in 96 well
Table 1. Imaging and Screening Statistics.
Exemplar resolution and imaging times for given pixel binning levels, using a 10  0.5 NA objective
and imaging our Tg(mbp:EGFP) reporter line. Fish loading times by LP Sampler to VAST BioImager
based on three fish per well (experiment averages 52 s for first fish and 17 s for subsequent two per
well). Combined loading and imaging rates per fish for different imaging parameters.
Pixel binning 1  1 2  2 3  3
Pixel Size (nm) 283 566 849
Exposure (ms) 180 45 20
Approximate Imaging Time (s/fish) 260 80 60
Fish loading time (s/fish) 30 30 30
Load and Image Rate (fish/hour) 5 tiles 12 33 40
Load and Image Rate (fish/hour) 1 tiles 43 78 85
DOI: https://doi.org/10.7554/eLife.35136.004
Video 2. Movie of maximum intensity projection of
stitched confocal stacks showing a 4 dpf Tg(mbp:EGFP)
animal demonstrating the ability of the VAST-SDCM
system to image myelinating glia at subcellular
resolution throughout the whole animal. Images
acquired at 10X, using 3  3 binning, pixel size 849 nm.
Refers to Figure 1.
DOI: https://doi.org/10.7554/eLife.35136.005
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Figure 2. Fully automated ROI specification in Tg(mbp:EGFP) larval zebrafish. (A) Schematic overview of 4 dpf larvae, illustrating the region (green
rectangle) of Tg(mbp:EGFP) animal imaged using VAST-SDCM (B). (C) Example fluorescence intensity profile from region demarcated by green dashed
lines in B. Each point on the profile is a sum of the grey values in X for a given Y position between the green dashed lines. (D) Along the length of the
spinal cord, each point of peak fluorescence is marked by a blue circle. The points identified in this way delineate the ventral spinal cord (E). This line
was then used to set regions of interest for dorsal and ventral spinal cord (F) and higher magnification view in G). Scale bars B, E and F = 250 mm,
D = 100 mm, and G = 50 mm.
DOI: https://doi.org/10.7554/eLife.35136.006
The following figure supplements are available for figure 2:
Figure supplement 1. Comparison of manual 3D vs manual 2D cell counting methods.
DOI: https://doi.org/10.7554/eLife.35136.007
Figure supplement 2. Analysis of plotROI function.
DOI: https://doi.org/10.7554/eLife.35136.008
Figure 2 continued on next page
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plate format (see Materials and methods). We found that 59/175 compounds were lethal at 100 mM,
22/175 at 10 mM, and 0/175 at 1 mM. Given that SKP2-C25 was effective in increasing oligodendro-
cyte number at 2 mM, and the absence of any lethal compounds in our library at 1 mM, we decided
to carry out our screen of myelinating oligodendrocyte number at 2 mM.
For our screen, Tg(mbp:EGFP) embryos were dechorionated and arrayed, three per well, into 96-
well plates at 1 dpf. Animals were treated with 2 mM compound at 2 dpf for 2 days (2–4 dpf), cover-
ing the developmental window in which OPCs are first specified, migrate and differentiate into oli-
godendrocytes that form myelin. At 4 dpf, larvae were imaged using the VAST-SDCM platform (see
above and Materials and methods) and effects on myelinating oligodendrocyte number were quanti-
fied using our fully-automated processes (Figure 5A and Materials and methods). Effects of com-
pound treatments on myelinating oligodendrocyte number were normalised against matched
DMSO-treated controls for each screening session and ranked by increase in cell number (Figure 5B
and Supplementary file 1 and 2). Of the 146 unique compounds tested, 14 were identified as hav-
ing a significant effect on oligodendrocyte number. Statistical analysis of individual experiments
(from single clutches) identified five compounds as significantly increasing cell number, including the
positive control SKP2-C25, and nine as decreasing, all assessed by Ordinary one-way ANOVA with
Dunnett’s post hoc multiple comparisons test (see Materials and methods and Table 2). Our positive
control compound was included in two independent screening runs, but only returned as a statisti-
cally significant hit in one of those runs. Interestingly, the screening run in which it was not identified
as a hit took twice as long to complete (8 vs 4 hr), reflecting the fact that variability in cell numbers
will increase with time, given ongoing development of live animals. Two compounds (ML-228 and
Trichostatin A) resulted in developmental lethality at the screening concentration used
(Supplementary file 1 and 2). To confirm that our fully automated image analysis was accurate and
did not itself lead to the creation of false positives or negatives, we compared the results from a sin-
gle screening session with manually-verified counts where the user could correct for any inaccurate
spinal cord selection or oligodendrocyte quantification (Figure 5C and Supplementary file 3). This
comparison demonstrated that the automated and manually adjusted analyses revealed essentially
identical effect sizes and identified the same hit compounds (Figure 5C and Supplementary file 3).
In agreement with previous literature on the critical role of histone deacetylation for oligodendro-
cyte development (Cunliffe and Casaccia-Bonnefil, 2006; Liu et al., 2016), we found several HDAC
(histone deacetylase) inhibitors in our set of 9 compounds that significantly reduced oligodendrocyte
cell number (Figure 5—figure supplement 1C and D, Table 2 and Supplementary file 1 and
2). The four novel compounds that significantly increased numbers of MBP-expressing oligodendro-
cytes in vivo (splitomicin, C646, NU9056, and
GSK-J5), have activity on diverse apparent tar-
gets. Of these, splitomicin, a sirtuin histone
deacetylase inhibitor (Bedalov et al., 2001), and
C646, a p300/CBP histone acetyltransferase
inhibitor (Bowers et al., 2010), were the most
effective in enhancing oligodendrocyte number,
both demonstrating a 73% increase compared to
controls (DMSO 41.7 ± 12.5 vs 2 mM splitomicin
72.3 ± 21.2 MBP +ve oligodendrocytes and
DMSO 34.3 ± 10.1 vs 2 mM C646 59.1 ± 14.3;
both p=0.0001; Supplementary file 1 and
2). NU9056, a selective KAT5 (Tip60) histone ace-
tyltransferase inhibitor (Coffey et al., 2012),
increased oligodendrocyte number by 56%
(DMSO 38 ± 18.9 vs 2 mM NU9056 59.2 ± 12.6,
p=0.013; Supplementary file 1 and 2). GSK-J5,
which shows weak inhibition for the jumonji
Figure 2 continued
Figure supplement 3. 3D-Cropping of images of complex transgenic animal.
DOI: https://doi.org/10.7554/eLife.35136.009
Video 3. Movie showing the automated process by
which fluorescent intensity profiles are calculated at
defined positions along the spinal cord of a 4 dpf Tg
(mbp:EGFP) animal to plot the position of the ventral
spinal cord. Refers to Figure 2.
DOI: https://doi.org/10.7554/eLife.35136.010
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family of histone demethylases,
(Kruidenier et al., 2012) increased myelinating
oligodendrocyte number by 41% (DMSO
38.4 ± 9.7 vs 2 mM GSK-J5 54.2 ± 9.1, p=0.003).
As our image acquisition pipeline also acquires
bright-field images of each larvae, one can imme-
diately also assess whether compounds give rise
to morphological phenotypes or developmental
toxicity (see examples in Figure 5—figure sup-
plement 1).
To assess the concentrations at which our four
novel hit compounds functioned, and to test the
possibility that we may have identified false posi-
tives, we carried out concentration series analyses
of hits at 0.5, 1, 2, 4, 10 and 20 mM using the
VAST-SDCM and refined ROI and refined counts
analysis. All four compounds were lethal at 10
and 20 mM. NU9056 re-treatment did not demon-
strate an increase in cell number at any concen-
tration (Figure 6), suggesting the possibility that
its identification in our screen represented a false
positive. However, splitomicin, C646 and GSK-J5 recapitulated the observed increases in oligoden-
drocyte number identified in the screen (Figure 6).
In summary, our automated screening pipeline represents an efficient, sensitive and unbiased
approach for the identification of novel compounds that can promote myelinating oligodendrocyte
formation.
Automated region-specific analyses to improve screening throughput
To extend the functionality of our image analysis pipeline and to further characterise the effects of
our hits, we wanted to assess whether the compounds identified in our screen elicited any region-
specific effects on myelinating oligodendrocyte formation. Therefore, we adapted our automated
image analysis script to record the x, y coordinates of each identified MBP +ve cell within the dorsal
spinal cord ROI and to plot the distribution of oligodendrocytes along the anterior to posterior (A-P)
axis in 100 mm bins (see Materials and methods and Figure 7B and D). This method identified a
greater proportion of mbp:EGFP expressing oligodendrocytes in the anterior region of the control
spinal cord, reflecting the known A-P gradient of oligodendrocyte development. As per our concen-
tration series, we found that retreatment of animals with NU9056 at its highest tolerated dose (4
mM) failed to show a significant increase in myelinating oligodendrocyte number, when all cells in
the dorsal spinal cord were assessed (Figure 7C). However, we found that NU9056 treatment
caused a clear increase in oligodendrocyte number in the anterior spinal cord, but no discernible
effect in the posterior spinal cord, which was also true of GSK-J5 (Figure 7B). In contrast, splitomi-
cin, C646 and SKP2-C25 exhibited a consistent increase in cell number along the A-P axis
(Figure 7D). Our region-specific assessment of hit compounds indicated that the region represent-
ing the second of five tiles along the length of the spinal cord was the most sensitive to changes in
myelinating oligodendrocyte number, wherein all five compounds had significant increases in myeli-
nating oligodendrocyte number (Figure 7E and Supplementary file 3). These data suggest that
analyses in single tile mode would be sufficient to detect hit compounds regulating cell number for
future screens. The region-specific effects may reflect timing of the A-P gradient of oligodendrocyte
lineage specification through to myelination with respect to the timing of our treatment (2 to 4 dpf),
rather than a region-specific effect per se. Imaging one instead of 5-tiled z-stacks per animal would
more than double the throughput of future screens, and allow us to assess myelinating oligodendro-
cyte number in 85 animals per hour, instead of the initial screen throughput of 40 per hour (Table 1).
Video 4. Movie showing the principle of the 3D
cropping macro, starting with travelling through the z
planes of a 3D dataset acquired on the VAST-SDCM of
a 4dpf Tg(mbp:nls-EGFP) animal. This is followed by a
maximum intensity projection through the Z-axis, with
the region to be kept highlighted in cyan. The
projection is then rotated through 90 degrees, to give
the Y-axis maximum intensity projection, which then
has the region to be retained highlighted in cyan. The
macro then removes any pixels not contained within
both regions to give the final 3D dataset, which is then
rotated back to the original orientation. Refers to
Figure 2—figure supplement 3.
DOI: https://doi.org/10.7554/eLife.35136.011
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Automated analysis of myelination
The myelin sheaths that are formed by oligodendrocytes during remyelination are abnormally short
and thin (Franklin and ffrench-Constant, 2017; Prineas and Connell, 1979). Therefore, the identifi-
cation of compounds that promote myelination per se may be important in restoring optimal neural
Figure 3. Automated cell counting allows for effective quantification of oligodendrocyte cell number. (A) Crop of
dorsal spinal cord of 4 dpf Tg(mbp:EGFP) zebrafish larva acquired on VAST-SDCM. (B) Output of ImageJ’s
findMaxima function (green dots), note that whilst not every cell is identified (e.g. the small dim cell indicated by
orange arrow in C), some cells are identified multiple times (green arrows in C). (C) Output of findMaxima plus
processCells function allows assessment of cell likeness, and removal of false positives, for example green arrows.
(D) Comparison of count methods for individual fish, with ROIs and cell counts verified and corrected by a human,
ROIs corrected by a human with automatic cell counts, and fully automated ROIs and cell counts.
DOI: https://doi.org/10.7554/eLife.35136.012
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circuit function via myelin regeneration
(Cole et al., 2017). To develop an assay to auto-
matically assess extent of myelination, we made
use of our transgenic reporter line Tg(mbp:EGFP-
CAAX), in which EGFP is targeted to the mem-
brane of MBP-expressing oligodendrocytes
(Figure 8A; [Almeida et al., 2011]). To quantify
changes in myelination, we first applied our land-
mark-based segmentation approach to select the
dorsal region of the spinal cord, as above for Tg
(mbp:EGFP). After ROI selection, we used
ImageJ’s ‘getRawStatistics’ function to quantify
the average fluorescence intensity throughout
the segmented region, as a proxy for the extent
of myelination (see Materials and methods). We
first tested whether this assay could identify the
known increase in myelination over time and
indeed found significant increases in mean fluorescence intensity in the dorsal spinal cord of our Tg
(mbp:EGFP-CAAX) from 3-4 dpf and 4–5 dpf, respectively (average dorsal grey values – 1  1 bin-
ning, 80 ms exposure, 3 dpf: 4.91 ± 0.68; 4dpf: 19.1 ± 6.41, p<0.0001 (3 vs 4 dpf); 5 dpf:
33.28 ± 11.44, p<0.0001 (4 vs 5 dpf); Figure 8—figure supplement 1). We next wanted to investi-
gate if our hit compound splitomicin exhibited an increase in myelination, according to this assay.
Automated quantification of splitomicin-treated larvae revealed a significant increase in mean dorsal
fluorescence intensity over multiple concentrations compared with control-treated larvae, despite
this being difficult to subjectively appreciate by eye (average dorsal grey values – 3  3 binning 60
ms exposure, DMSO 136.1 ± 35.9 vs 2 mM splitomicin 174.7 ± 34.3, p=0.0023; 3 mM splitomicin
186.4 ± 33.3, p=0.0001; 4 mM splitomicin 203.4 ± 38.3, p=0.0001 Figure 8B). To confirm that this
increase in fluorescence did indeed reflect a change in bona fide myelination, we performed trans-
mission electron microscopy on 4 dpf larvae and found a ~1.8 fold increase in myelinated axon num-
ber in splitomicin-treated animals (DMSO 9.8 ± 4.3 vs 2 mM splitomicin 18 ± 2.6, p=0.0065;
Figure 8C–E). Therefore, our fluorescence intensity-based assay provides an unbiased, automated
approach for the quantification of myelination in vivo, with higher sensitivity than subjective manual
assessment. Future screens will be carried out to identify compounds that can promote myelination
in and of itself.
Finally, to test whether compound function in zebrafish was conserved in mammals, we tested
whether treatment of rat primary oligodendrocytes with splitomicin also affected the mammalian oli-
godendrocyte lineage. Indeed, we found that two-day treatment of cultures immediately following
plate-down (see Materials and methods) resulted in a robust increase in the number of MBP express-
ing oligodendrocytes (Figure 9). Furthermore, we assessed proliferation (using an antibody recog-
nising Ki67) of oligodendrocyte lineage cells (using an antibody recognising olig2). We saw an
increase in the number of Ki67-expressing, olig2-expressing cells, upon splitomicin treatment (Fig-
ure 9), indicating that the observed increase in
myelinating oligodendrocyte number was due to
increased proliferation and subsequent differenti-
ation of a larger pool of OPCs. Therefore, our
identification of splitomicin as a regulator of the
oligodendrocyte lineage in zebrafish was vali-
dated as having the capacity to regulate the
mammalian oligodendrocyte lineage. Future
studies will investigate the conservation of func-
tion of our other hits in the mammalian oligoden-
drocyte lineage.
Video 5. Movie showing circa real-time speed of
automated ventral spinal cord demarcation, dorsal
spinal cord ROI selection and cell counting per animal.
Refers to Figures 1–3.
DOI: https://doi.org/10.7554/eLife.35136.013
Video 6. Time-lapse movies of Tg(Olig2:GFP), Tg
(sox10:mRFP) double transgenic control (top) and SKP-
C25-treated (bottom) embryos imaged between 58 hpf
and 70 hpf. Refers to Figure 4—figure supplement 1.
DOI: https://doi.org/10.7554/eLife.35136.014
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Discussion
Here we describe the development of a fully automated, sub-cellular resolution, in vivo chemical
screening pipeline, which we have used to identify compounds that promote myelinating oligoden-
drocyte formation in zebrafish. By combining the now commercially available LP Sampler and VAST-
BioImager (both Union Biometrica) with a spinning disk confocal microscope (VAST-SDCM), we
Figure 4. Validation of automated image analysis to identify changes in myelinating cell number induced by
chemical hit. (A, B) Confocal images of Tg(mbp:EGFP) control (A) and SKP2-C25-treated (B) animals reflecting
mean cell number per treatment (numbers refer to entire dorsal spinal cord, not magnified area of same animals).
Scale bar = 100 mm. (C) Quantitation of cell number in control and SKP2-C25 treated animals using fully
automated (grey bars) and refined counts, auto ROIs (black bars). Two-way ANOVA followed by Dunnett’s multiple
comparison test was used to assess statistical significance, with multiple comparison adjusted P value presented
as *p<0.05, ***p<0.001. Error bars represent means ± s.d.
DOI: https://doi.org/10.7554/eLife.35136.015
The following figure supplement is available for figure 4:
Figure supplement 1. SKP2-C25 increases proliferation of OPCs in the dorsal spinal cord.
DOI: https://doi.org/10.7554/eLife.35136.016
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Figure 5. Automated chemical screening pipeline in zebrafish identifies novel regulators of oligodendrocyte
development. (A) Schematic of chemical screening pipeline. (B) Results of primary screen displayed as normalised
fold change in oligodendrocyte number relative to matched DMSO-treated controls and ranked by cell increase
for all 183 treatments (146 unique compounds) with hit compounds that increase or decrease cell number marked
in green and toxic compounds in red. Inset shows ranking of compounds that significantly increased
oligodendrocyte cell number. See also Table 2 and Supplementary file 1 (C) Quantification of dorsal
Figure 5 continued on next page
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automated the delivery, orientation, and high-speed, sub-cellular resolution imaging of zebrafish.
We developed an image handling and analysis pipeline that automates file handling tasks, and which
also allows assay-specific operations including region of interest selection and a variety of quantita-
tive assessments, such as analyses of cell number, distribution, shape and fluorescence intensity. We
have implemented and exemplify the power of this pipeline to identify compounds that regulate
myelinating oligodendrocyte lineage formation. Importantly, our imaging platform and image analy-
sis scripts can in principle be adapted to execute a variety of assays relevant to numerous biological
processes of interest to the community. Our custom scripts are freely available at https://github.
com/jasonjearly/VAST-SDCM (Early, 2018; copy archived at https://github.com/elifesciences-publi-
cations/VAST-SDCM).
Scaling up and refining high-resolution quantitative in vivo screens
Here we demonstrate the power of the VAST-SDCM platform and automated image handling and
analysis scripts by carrying out a small screen of compounds, which were tested for their ability to
promote oligodendrocyte lineage progression. We identified three novel compounds that reproduc-
ibly increased myelinating oligodendrocyte number (C646, GSK-J5 and splitomicin). However, each
of these compounds, and our positive control compound, SKP2-C25, functioned over a relatively
tight concentration range, and exhibited somewhat variable effects. Indeed, SKP2-C25 only served
its function as a positive control one out of the two times that it was tested in the screen, and C646
only exhibited statistically significant increases in oligodendrocyte number in one of the three times
Figure 5 continued
oligodendrocyte number from a single screening session showing comparison of different analysis methods.
*p<0.05, ****p<0.0001. Error bars represent means ± s.d.
DOI: https://doi.org/10.7554/eLife.35136.017
The following figure supplement is available for figure 5:
Figure supplement 1. Example hits identified from our primary screen as regulators of oligodendrocyte
development.
DOI: https://doi.org/10.7554/eLife.35136.018
Table 2. Significant Hits From Screen.
Fold change in oligodendrocyte number induced by individual hit compounds normalised to DMSO
treated controls in appropriate treatment plate. For complete list of compound effects and putative
targets, see Supplementary file 1.








Suberohydroxamic Acid 0.65 0.0043
IOX1 0.56 0.0003
CUDC-907 0.37 0.009
PI3K/HDAC Inhibitor I 0.30 0.0006
(+)-JQ1 0.29 0.0001
JIB-04 (NSC693627) 0.08 0.0001
Trichostatin A 0.06 0.0001
DOI: https://doi.org/10.7554/eLife.35136.019
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it was screened, although it did have trend increases of similar effect size all three times (see
Supplementary file 1 and 2). Interestingly, the durations of screening runs in which these com-
pounds were not returned as hits were longer than those from which they were, reflecting the fact
that variability in cell number will increase over time, given that continuously developing live animals
are being examined. The false negatives may also be due to the narrow concentration windows of
efficacy (Figures 4 and 6), coupled with the fact that researchers typically don’t assess actual
Figure 6. Concentration series and chemical structures of hit compounds from screen. For each hit identified in the primary screen, repeat treatments
were carried out as before (12 fish treated from 2-4dpf), with either 1% DMSO, 0.5 mM, 1 mM, 2 mM, 4 mM, 10 mM or 20 mM of the hit treatment. For all
compounds, the 10 and 20 mM treatments were fatal and are not shown on the above graphs. Chemical structures of each hit are displayed in
respective graphs. One-way ANOVA followed by Dunnett’s multiple comparison test was used to assess statistical significance, with multiple
comparison adjusted P value presented as *p<0.05, **p<0.01, ****p<0.0001. Error bars represent means ±s.d.
DOI: https://doi.org/10.7554/eLife.35136.020
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Figure 7. Automated region-specific analyses of identified hit compounds. (A) Representative single tile images of
4 dpf Tg(mbp:EGFP) larvae following treatment with the five hit compounds that increased oligodendrocyte
number in our screen. Scale bar, 100 mm. Mean numbers of dorsal oligodendrocytes quantified for each treatment
and in the examples shown are indicated above each corresponding image. (B) Plot of the anterior-posterior
Figure 7 continued on next page
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compound concentration prior to a screen. These examples serve to highlight the issue of false neg-
atives that need to be addressed with any chemical screening platform. To reduce variability due to
protracted screening runs, we recommend screening individual compounds over shorter periods of
time, when using live animals, by adjusting their distribution across screening plates accordingly. In
addition, to mitigate false negatives due to restricted windows of efficacy, one could carry out high-
resolution screens at multiple concentrations within doses well tolerated by the animal. This would
clearly require the processing of more animals per screen and represent a trade-off between
increased throughput and reduced error rate. We have demonstrated that for our oligodendrocyte
cell number assay, imaging and screening a single tile instead of the entire animal would have been
as effective in hit identification, and more than halved the screening time. This would have allowed
us to assess about 85 animals per hour, instead of 40. To further scale up screening capacity on this
platform, another option may involve pooling distinct compounds, and assessing the ability of pools
to elicit phenotypes. One could then subsequently identify the effective compound(s) in the active
pool(s). The pooling of compounds is most likely to be effective for compounds with limited toxicity
and thus will differ library to library. However, this may be an effective way in which to greatly scale
up the utility of the VAST-SDCM system.
To best ensure reliability of screens and to reduce error rates in so far as possible, the use of pos-
itive controls and appropriate powering of experiments is essential. We would advise investigators
initiating quantitative screens that aim to identify subtle phenotypes to run robust positive controls
throughout individual screening runs where possible. Prior to the initiation of our screen, our power
calculations indicated that a reduced n = 6 would have had a power of 80% to detect changes in cell
number of 35% (vs 95% for n = 9, which we scaled to 12 to account for occasional failure to image
samples correctly). Indeed, the success rate of fish loading through to automated data analysis was
80% across the entire screen, meaning that on average our actual n was just over nine per condition.
Following our screen, we analysed our raw data and assessed what hits we would have identified, if
we compared our actual n for each hit compound compared to n = 6 or n = 3 (Supplementary file
4). Interestingly, at an n = 6 only C646 and SKP2-C25 would have been identified as hits, and the
absence of identifying the validated hits splitomicin and GSK-J5 would have represented false nega-
tives. In addition, at the lower n values, we would have identified one false positive hit at n = 6 and
two at n = 3 (Supplementary file 4), and incurred six false negatives at n = 6 and 12 at n = 3
(Supplementary file 4).
Our desire to test the ability of the system to identify hits that regulated cell number by 35% was
stringent. If a larger effect size threshold was used, then a lower ‘n’ would suffice. For example, if we
defined a criterion for a hit as having the ability to change myelinating cell number by >75% with
95% power, then in principle an n of 3 would suffice. Therefore, in the design of any quantitative
screen, one needs to consider the definition of what constitutes a hit and to power the analysis
based on known variability in the parameter being assessed accordingly.
Novel regulators of oligodendrocyte formation
Following our screen, we identified and validated four compounds that promote myelinating oligo-
dendrocyte formation in larval zebrafish. Splitomicin is a small molecule inhibitor of the sirtuin family
of NAD+-dependent HDACs (Bedalov et al., 2001), with reported activity for sirtuin 1 and 2 (sirt1
and sirt2) in mammalian cells in vitro (Pasco et al., 2010). Sirt1 shows broad protein expression
throughout the rodent CNS (Sidorova-Darmos et al., 2014), but has been implicated in regulating
the oligodendrocyte lineage. For example, conditional genetic inactivation of sirt1 in adult rodent
neural stem cells led to an increase in OPC formation, and a consequent increase in remyelination
following toxin-induced demyelination (Rafalski et al., 2013). Interestingly, the opposite effect on
Figure 7 continued
distribution of dorsal oligodendrocytes along the spinal cord demonstrates region-specific effects with NU9056
and GSK-J5 treatment, whereas C646, SKP2-C25 and splitomicin exhibit more consistent increases in cell number
along the A-P axis (D). (C) Quantification of oligodendrocyte number throughout the entire dorsal region shows
lower sensitivity for identifying compounds with region-specific effects compared with quantification within one tile
region (second of five tiles) (E). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Error bars represent means ± s.d.
DOI: https://doi.org/10.7554/eLife.35136.021
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Figure 8. Treatment with splitomicin increases spinal cord myelination in vivo. (A) Representative images of myelin within the spinal cord of control
(top) and splitomicin-treated (bottom) Tg(mbp:EGFP-CAAX) larvae. Scale bar, 50 mm (B) Quantification of mean fluorescence intensity throughout the
entire dorsal spinal cord demonstrates a significant increase following 2–4 mM splitomicin treatment from 2-4 dpf. (C) Schematic of a transverse section
through the zebrafish spinal cord shows the position of myelinated axons (blue) in relation to the gray matter (neuronal cell bodies are coloured in
grey). Red box indicates approximate area shown in (D) in which myelinated axon number was quantified. (D): Transmission electron micrographs of
control (left) and splitomicin-treated (right) larvae at 4 dpf with myelinated axons pseudo-coloured in blue. Scale bar, 1 mm (E) Numbers of myelinated
axons in the dorsal spinal cord are significantly increased following 2–4 dpf treatment with 2 mM splitomicin. **p<0.01, ****p<0.0001. Error bars
represent means ± s.d.
DOI: https://doi.org/10.7554/eLife.35136.022
The following figure supplement is available for figure 8:
Figure supplement 1. Automated fluorescent quantification of myelin during development.
DOI: https://doi.org/10.7554/eLife.35136.023
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the oligodendrocyte lineage has been reported in neonatal animals, with reduced numbers of prolif-
erating OPCs following sirt1 knockdown and increased oligodendrocyte differentiation under hyp-
oxic conditions suggesting a context-dependent role for sirt1 (Jablonska et al., 2016). In contrast to
sirt1, sirt2 expression is highly enriched in the oligodendrocyte lineage, and is upregulated in newly
differentiating and myelinating oligodendrocytes (Werner et al., 2007; Zhang et al., 2014).
Figure 9. Splitomicin enhances mammalian oligodendrocyte generation in vitro. (A) Representative images of rat oligodendrocyte cultures treated with
1% DMSO or 3 mM splitomicin, stained for antibodies that recognise MBP, Olig2 and Ki67. Scale bar = 50 mm. (B–D) Quantification of Olig2+ cell
number (B), MBP+ cell number (C) and Ki67+ Olig2+ cell number (D). Shapiro-Wilk normality test determined that datasets were not normally
distributed. Therefore, a Kruskal-Wallis test was followed by Dunn’s multiple comparison test to test statistical significance between conditions.
*p<0.05, **p<0.01. Error bars represent means ± s.e.m.
DOI: https://doi.org/10.7554/eLife.35136.024
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However, despite its specific expression in the oligodendrocyte lineage, the role of sirt2 in regulat-
ing oligodendrocyte differentiation and myelination remains somewhat unclear (Ji et al., 2011;
Li et al., 2007). Our data suggest that splitomicin increases myelinating oligodendrocyte number in
both zebrafish and rat, but it remains unclear whether these effects are mediated via sirt1 and/or
sirt2 or indeed on another unknown target. Therefore, the validation of targets engaged by hit com-
pounds, by genetic and biochemical means, is essential to disentangling the mechanistic basis of
compound function. In addition, future genetic investigation of the role of prospective targets in a
cell-type specific manner will be required to explore their relative roles in the oligodendrocyte line-
age and in other cell types. Although we did not see general effects on animal development with
our hit compounds, we cannot rule out roles in other cells, particularly as these regulators are
broadly expressed. Our second ranked hit, C646, is a competitive inhibitor of the CBP/p300 family
of histone acetyltransferases (HATs) (Bowers et al., 2010). As transcriptional co-activators, CBP and
p300 have been implicated in coordinating cell fate decisions through their interactions with numer-
ous histone and non-histone related proteins in vitro (Nakashima et al., 1999; Zhang et al., 2016).
Notably, CBP can acetylate the transcription factor olig1 and regulate its nuclear to cytoplasmic
localisation, which is associated with oligodendrocyte differentiation (Dai et al., 2015), and p300 lev-
els have been shown to be altered in a subset of patients with MS (Pedre et al., 2011). The third
novel hit that was validated in all subsequent assays, GSK-J5, displays weak activity for the jumonji
(JMJ) family of histone demethylases in mammalian in vitro assays and for this reason is recom-
mended as a structure-matched inactive control for the more active isomer, GSK-J4
(Kruidenier et al., 2012). This fact, coupled with the finding that GSK-J4 and other selective JMJ
inhibitors within the library had no effect on oligodendrocyte number in our screen, suggests that
GSK-J5 may promote myelinating oligodendrocyte formation through an alternative target, again
highlighting the issue of target validation (Schenone et al., 2013). From the point of view of both
hit and target validation, it is important to note the value of using multiple compounds (ideally struc-
turally diverse) that are purported to hit the same target. Given that most compounds are likely to
bind to more than one target in vivo, if several compounds with an overlapping target elicit the
same phenotype, then one has a better foundation upon which to pursue the more challenging
genetic and biochemical methods of target validation.
Our pilot screen identified hits that robustly increase myelinating oligodendrocyte number. How-
ever, extensive further studies will be required to fully characterise the mechanisms by which these
compounds affect specific stages of the oligodendrocyte lineage. The ability to carry out time-lapse
imaging of oligodendrocyte lineage progression in vivo using zebrafish offers a great advantage in
assessing when compounds mediate their functions, as shown for SKP2-C25 (Figure 4—figure sup-
plement 1 and Video 6). Future time-lapse studies will explore how our other hit compounds affect
the dynamic development of the oligodendrocyte lineage in vivo. In addition, the development of
further stage-specific reporters and markers in zebrafish coupled with complementary studies in cell
based platforms allow further dissection of the timing and cellular mechanisms of compound
activities.
Versatility and future potential of the VAST-SDCM platform
We exemplify the potential of the VAST-SDCM system for discovery screens using a transgenic
reporter of myelinating oligodendrocytes, and myelination, but essentially any reporter of interest
can be imaged using this platform. The system has multiple excitation laser lines and two cameras
that allow simultaneous imaging in two channels without any increase in imaging time, meaning that
two assays could be screened in parallel, given appropriate reporters, or several reporters in parallel
with some increase in imaging times. In addition, the platform can accommodate photo-ablation
and photo-activation lasers for acute manipulations, and the stability of larvae in the imaging capil-
lary, and speed of the SDCM imaging system is such that up to minutes long time-lapse microscopy
could, in principle, be carried out on individual animals. A recent update to the liquid handling sys-
tem now means that the platform can be configured such that zebrafish can be dispensed back in to
the wells of multi-well plates from the BioImager, allowing for collection of embryos for further
study, for example genotyping or re-imaging.
In addition to the obvious versatility of the imaging platform, we have also extended our image
analysis scripts to provide additional functionalities. One common issue when dealing with fluores-
cently labelled reporters or markers is expression in tissues outwith areas of interest, or disruptive
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auto-fluorescence, for example in the zebrafish skin. To exemplify this utility, we segmented the spi-
nal cord from its surrounding peripheral tissue in Tg(mbp:nls-EGFP) animals, which also express
nuclear-localised EGFP in peripheral Schwann cells (Figure 2—figure supplement 3, Video 4, and
see Materials and methods). In principle, our landmark-based segmentation approach can be imple-
mented in a case by case reporter-dependent manner for selection of 3D ROIs. However, in situa-
tions where there are no opportunities to assign a reference landmark, one could assign ROIs by
determining average distances from the reference landmark in our transgenic reporters. We exe-
cuted our screen using 2D images, because we found that cell number could be as accurately
assessed from 2D MIPs as 3D z-stacks. However, in some cases information on the 3D nature of
manipulations will be of importance. Therefore, we added another optional functionality to our
image analysis pipeline, which allowed us to encode quantitative information relating to individual
images in a z-stack in 2D MIP images (Figure 2—figure supplement 3 and see Materials and meth-
ods). This approach has the benefit of allowing one to assess effects of experimental manipulations
in 3D without the storage and processing issues associated with dealing with high-content 3D imag-
ing datasets. In general, it is desirable in a screen to maximise data use and minimise costs (mone-
tary and time) associated with storage and processing of very large datasets.
In addition to serving as a powerful discovery system, zebrafish present numerous advantages for
the deep phenotypic characterisation of compound function on biological processes. In particular,
their suitability for live imaging and the myriad transgenic reporters of various molecules, cells and
tissues, allow the effects of compounds on cell behaviours to be followed with high spatial and tem-
poral resolution in the living animal in ways that are hard to achieve in other vertebrates (Bin and
Lyons, 2016). Furthermore, the ability to directly observe tissue development and health at scale
and over time-scales of days, presents remarkable advantages for drug development projects that
need to triage chemical structures with possible deleterious effects. In addition to serving as a plat-
form for phenotypic discovery screens, the VAST-SDCM is also suited to more focussed target-
driven studies, for example the profiling of arrays of compounds designed to hit individual targets.
Coupled with the capacity to image essentially any molecule, cell, or tissue type with a sufficiently
robust fluorescent reporter, the VAST-SDCM platform provides a versatile option for scalable
(medium–throughput) high-resolution focussed approaches. Automated higher-throughput, lower
resolution in vivo screening capacities have recently also been demonstrated using zebrafish
(Wang et al., 2015). The availability of screening options at multiple scales highlights the power of
zebrafish as a discovery model. We expect that our implementation of VAST-SDCM and our adapt-
able image handling and analysis scripts will be of value to the wider research community, and we
invite interested users to contact us.
Materials and methods
Zebrafish husbandry and transgenic lines
Adult zebrafish were housed and maintained in accordance with standard procedures in the Queen’s
Medical Research Institute zebrafish facility. All experiments were performed in compliance with the
UK Home Office, according to its regulations under project licenses 60/4035 and 70/8436. Adult
zebrafish were subject to a 14/10 hr, light/dark cycle. Embryos were produced by pairwise matings
and raised at 28.5˚C in 10 mM HEPES-buffered E3 Embryo medium or conditioned aquarium water
with methylene blue. Embryos were staged according to hours or days post-fertilisation (hpf or dpf).
The following transgenic lines were used for this study: Tg(mbp:EGFP) (Almeida et al., 2011), Tg
(mbp:EGFP-CAAX) (Almeida et al., 2011), Tg(mbp:nls-EGFP) (Karttunen et al., 2017), Tg(olig2:
EGFP) (Shin et al., 2003) and Tg(sox10:mRFP) (Kirby et al., 2006).
Hardware setup (VAST-SDCM platform)
We used the Large Particle (LP) Sampler and VAST BioImager (Union Biometrica) to automate the
delivery of zebrafish from the wells of multi-well plates to the BioImager microscope platform. To
combine the power of the VAST BioImager platform to automatically orient zebrafish within a thin-
walled glass capillary according to user-defined templates with high-speed imaging, we mounted
the BioImager platform on an upright Axio Examiner D1 (Carl Zeiss) microscope, fitted with a high-
speed CSU-X1 spinning disk confocal scanner (Yokogawa, Tokyo, Japan). All animals were imaged
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from a lateral view. In order to optimise the field of view, we added a 1.6X post-magnification adap-
tor to the light path, which when combined with a C-Plan-Apochromat 10X (0.5NA) dipping lens
(Carl Zeiss) and dual AxioCam 506 m CCD cameras (Carl Zeiss), allowed acquisition of images with
X-Y dimensions of 662 mm x 492 mm, such that the majority of the capillary’s 600 mm Y-axis could be
captured. The imaging system was configured with 50 mW 405 nm, 50 mW 488 nm and 20 mW 561
nm lasers and two AxioCam 506 m CCD cameras, high-speed emission filter wheel with 450/50,
520/35 and 527/54 + 645/60 nm emission filters for camera 1, and a fixed 630/98 nm emission filter
for simultaneous acquisition.
To ensure rapid image acquisition in the z-plane, we employed a long-range, high-speed PIFOC
P-725.4CD piezo objective scanner (Physik Instrumente, Karlsruhe, Germany), capable of up to 400
mm high speed travel.
The VAST BioImager microscope platform can be moved in the x, but not y-axis. To generate
stitched z-stacks the system needs to hand control back and forth (via Transistor-Transistor Logic,
TTL, commands, Figure 1) between the VAST BioImager software (Union Biometrica) and the micro-
scope’s image acquisition software, Zen Blue 2.0 (Carl Zeiss). This allows interspersed rounds of
acquisition of individual z-stacks and movement of the BioImager platform in the x-axis (Figure 1).
For higher resolution imaging, a C-Plan Apochromat 20X (1NA) dipping lens (Carl Zeiss) was
employed.
Custom software
All custom software and scripts used in this work are freely available at https://github.com/jason-
jearly/VAST-SDCM (Early, 2018).
Automation of file handling
All file handling was automated using custom ImageJ Macro Language (IJM) scripts
(Schindelin et al., 2012; 2015). Due to the nature of the communication between the VAST BioIm-
ager and microscope (a simple TTL signal), the images acquired by the microscope contain no fish or
well-specific information. To overcome this issue, our image processing scripts include functions to
cross reference image acquisition times with the VAST BioImager signal times (recorded by VAST in
a .csv file) for specific tile locations for individual fish for each well sampled. This data was then used
to concatenate upper and lower z-stacks, stitch tiles of z-stacks, generate maximum intensity projec-
tions of tiled z-stacks, and finally to perform cell counts. File stitching was carried out using FIJI’s
inbuilt Grid/Collection Stitching plugin (Preibisch et al., 2009). Additional quality control checks
were applied to the output of the stitching plugin to ensure that stitched image dimensions fell
within a given tolerance of those expected. Any images outwith these dimensions are highlighted to
the user. This file management process is carried out by the Process_VAST_v1.1.ijm macro
(Early, 2018).
Automation of ROI selection
ROI selection was performed using the plotROI function of our custom image analysis script, Count-
Cells_2D_v1.1.ijm (Early, 2018). This function first identifies the ventral spinal cord of the Tg(mbp:
EGFP) transgenic zebrafish line by repeated sampling of 150 mm blocks of the image along the
x-axis, with the sum of grey values for each y-position within a block used to identify the peak fluo-
rescence in y for the block (see Figure 2). This process was carried out using the getProfile function
of ImageJ for a line of width 150 mm. The stereotyped nature of the fluorescence in this transgenic
line means that the identified peaks delineates the ventral spinal cord of the embryo. Due to the
sparse distribution of cells in the posterior spinal cord, an additional step was added to find the final
cell. A best fit straight line was produced from the last four successful ventral spinal cord points and
extrapolated caudally. This line was sampled to identify the last potential cell falling within 20 mm,
above or below this best fit (Figure 2).
Using the line representing the ventral spinal cord of the fish, regions of interest were then set for
the dorsal and ventral spinal cord, as well as the entire structure. Polygon regions are created with
characteristic dimensions. In addition, in order to mimic the narrowing of the spinal cord, the dorsal
region was tapered linearly towards half its original height, at the posterior (Figure 2). All regions of
interest were then saved for subsequent inspection or repeated measurements.
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Whilst this method has been used to segment the dorsal spinal cord using the Tg(mbp:EGFP)
reporter, the principle of this technique could be broadly applied to other structures of interest.
Automated cell counting
Cell counts were carried out using the CountCells_2D_v1.1.ijm macro (Early, 2018). Cell counting
was first performed within the regions identified by the plotROI function, using ImageJ’s findMaxima
function. The findMaxima function requires an input threshold which sets the minimum difference in
fluorescence between two potential maxima to allow them to be identified as distinct peaks (i.e. the
minimum drop in fluorescence between two peaks).
Whilst initial tests showed that the findMaxima function was able to identify differences between
positive and negative control treatments, at lower input threshold values, many false positive points
were produced (data not shown). At these lower thresholds, brighter cells possess multiple maxima,
due to lack of fluorescence homogeneity (green arrows in Figure 3), while at even lower thresholds,
background noise may be identified as a cell.
To prevent over assignment of false positive hits using the findMaxima function, the processCells
function was developed to refine the raw findMaxima point selection. For each point identified by
the findMaxima function, ImageJ’s doWand function was used to select connected pixels (with a tol-
erance of half that point’s peak intensity). Statistics were then produced for the putative cell using
the getStatistics and ROI.getBounds functions of ImageJ. The size and shape of the produced selec-
tion were then assessed for cell likeness, and false positives removed. Additional cell likeness criteria
(such as minimum, maximum or standard deviation of fluorescence intensity) can readily be applied
by minor modification to the processCells function. Maxima which did not fit the cell likeness criteria
were discarded, and refined point as well as polygon outline selections were saved for further analy-
sis (see binned cell counts method, below). Appropriate thresholds were identified for a given data-
set using the intelligentThresh function. This function takes user adjusted cell counts from five
randomly selected fish and identifies the threshold which gave the closest match to the human cell
count.
Binned cell counts
The relative distribution of cells along the length of the spinal cord was automatically determined
using a custom ImageJ script (see script Plot_Distribution_v1.1.ijm, Early, 2018). This script takes
the point selection and the ventral spinal cord selection produced by the cell counting script, for
each fish, and assigns an x-coordinate to each point. This x-coordinate was calculated by identifying
the closest point on the ventral spinal cord to each cell. This calculation was necessary to account for
the variable curvature of the spinal cord as well as any minor fish positioning errors. Cell numbers
were then binned based on these calculated x-positions.
Tg(mbp:EGFP-CAAX) intensity measurements
Relative quantities of myelin were estimated between treatments using ImageJ’s ‘getRawStatistics’
function, which measured the mean grey value within the whole zebrafish spinal cord, as selected by
the plotROI function, with manual user adjustment of the ventral spinal cord selection to ensure an
accurate selection. The measurement was performed on stitched maximum intensity z-projections
for each fish, using an adapted version of the CountCells_2D macro, see CAAX_Analysis_v1.1.ijm
(Early, 2018).
3D volume segmentation
A custom ImageJ script (see script 3D_Crop_v1.1.ijm, Early, 2018) was written to present a user
with orthogonal maximum intensity projections of a z-stack, to which selections may be made and
added to ImageJ’s ROI manager. The script identifies ROIs wholly contained within the xy, xz or yz
regions, and sets all pixels outside these regions to 0 for all slices, in their respective view. This cre-
ates an AND effect, where only pixels included in all ROIs are retained. The script outputs a new
z-stack with the retained pixels and, optionally, the discarded pixels.
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Depth projection
To efficiently map the depth of maximum intensity for each pixel in xy of acquired z-stacks, the
inbuilt ImageJ ZProjector plugin was adapted (see D_Projector_v1.1.jar, Early, 2018) to record this
information in a secondary 2D image (termed the depth projection, or dProj). This secondary dProj
image was then masked with the cell profiles created by the processCells function, and any non-cell
pixel set to 0 for the purposes of illustration (Figure 2—figure supplement 3D). A lookup table was
applied to the subsequent image to illustrate the additional contrast possible with this method.
Sample size calculation
A sample size calculation was performed using the method described recently by (White et al.,
2016). The following equation was used to calculate the required sample size (n), based on a sample









Where s, Zb, Za, mr and mh are standard deviation (of control with largest variance), required
power, required level of statistical significance, mean of positive control group and the mean of neg-
ative control group respectively.
Chemical screen: larvae preparation and compound treatments
Out-crosses of the Tg(mbp:EGFP) transgenic line were used for the primary screen. At 24 hpf,
embryos were enzymatically dechorionated using protease from Streptomyces griseus (0.5 mg/mL
for 6 min) (Sigma-Aldrich, St. Louis, MO) and manually arrayed into 96-well plates in a volume of 225
mL E3 media (three embryos per well). At 48 hpf, larvae were checked for viability, and any unhealthy
animals were manually removed and replaced in equal volumes with clutch-matched larvae. 10 mM
compound stocks in DMSO (Xcess Biosciences, San Diego, CA; SelleckChem, Houston, TX; Cayman-
Chem, Ann Arbor, MI) were serially diluted using a multi-channel pipette to a 4X concentrated treat-
ment solution. Between 48–51 hpf, 75 mL of this 4X stock was added directly into the larval wells for
a final concentration of 2 mM in 1% DMSO. Each compound was tested on 4 wells of 3 fish per well
(n = 12) and compared against 1% DMSO negative controls within the same plate. Treatment plates
were then kept within secondary chambers to reduce evaporation and incubated under standard
temperature conditions for 2 days without compound refreshment. At four dpf, larvae were anaes-
thetised with 600 mM tricaine prior to imaging. For the preliminary qualitative screen, embryos were
manually mounted in 1.1% low-melting agarose (Invitrogen) on a glass coverslip, and suspended
over a microscope slide using high vacuum silicone grease to create a well containing embryo
medium and 600 mM tricaine.
Treatments were imaged such that replicate wells were imaged throughout the day (i.e. Treat-
ment 1 well 1, Treatment 2 well 1, Treatment 3 well 1. . ., Control well 1, then Treatment 1 well 2,
Treatment 2 well 2, Treatment 3 well 2. . ., Control well 2. . .), to spread any variability due to devel-
opment whilst imaging live animals over time.
Time-lapse imaging
For time-lapse imaging Tg(sox10:mRFP; olig2:GFP) larvae were used. Zebrafish larvae were treated
at 48 hpf with SKP2-C25 (1% DMSO). At 56–57 hpf, larvae were anaesthetised in 600 mM tricaine
and manually mounted in 1.5% low melting point agarose in embryo medium containing either
SKP2-C25 (1% DMSO) or 1% DMSO and 600 mM tricaine. Time-lapse imaging was performed using
a Zeiss LSM710 confocal microscope (Carl Zeiss) with a temperature controlled stage set to 28.5˚C
throughout imaging. Images of the middle region of the spinal cord (somite 15 = centre of image)
were acquired using a 20X objective (Zeiss Plan-Apochromat 20X dry, NA = 0.8), zoom 1, corre-
sponding to a 425 mm region of the spinal cord. Dual colour Z-stacks (488 and 594 nm lasers) were
acquired every 14 min over 16 hr of the full depth of the spinal cord with 2 mm Z-interval. Larvae
were checked the following morning for viability and general health with any unhealthy animals
excluded from analysis. For analysis, maximum-intensity projections were made for each time point
over the 16 hr imaging period. To reduce x-y drift, dual-colour images were registered using the
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olig2:EGFP channel and ‘Register virtual stack slices’ plugin in Fiji. The ‘Transform virtual stack slices’
plugin was then used to apply the same transformations to the sox10:mRFP channel. Dorsal OPC
migration and proliferation events were manually quantified over a 12 hr period from 58 to 70 hpf
using the Cell Counter plugin in Fiji.
In vitro OPC differentiation assay
Cortical mixed glial cultures were generated from Sprague Dawley rats P0-2, as described previously
(McCarthy and de Vellis, 1980). After 10–12 days of expansion oligodendrocyte progenitor cells
were mechanically separated, counted and grown on poly-D-lysine coated 18 mm coverslips at a
density of 75,000 cells per well. Cells were grown in myelination media: 50:50 DMEM:Neurobasal
Media, B27 supplement, 5 mg/mL N-acetyl cysteine, and 10 ng/mL D-biotin, ITS and modified Sato
(100 mg/mL BSA fraction V, 60 ng/ml Progesterone, 16 mg/ml Putrecsine, 400 ng/mL Tri-iodothyrox-
ine, 400 ng/mL L-Thyroxine), at 37˚C in 7.5% CO2. Treatments were added at plating and refreshed
after 24 hr.
Cells were fixed after 48 hr with 4% PFA for 15 min and blocked for 30 min in 10% goat serum
and 0.1% triton-X-100 at room temperature. Primary antibodies were diluted in blocking solution
and applied overnight at 4˚C: mouse anti-Olig2 (1:200, Millipore; MABN50), rat anti-MBP (1:250;
AbD Serotec; MCA409S) and rabbit anti-Ki67 (1:250; Abcam; ab16667). Cells were incubated with
fluorescently conjugated secondary antibodies diluted in blocking solution (1:1000, Life Technolo-
gies-Molecular Probes), for 1 hr at room temperature and counterstained with Hoechst (5 mg/ml).
Five random images were taken per coverslip on a Leica SP8 confocal microscope (20X objective)
and counted using ImageJ, double blind to condition. A Shapiro-Wilk normality test was used to
determine normality of distribution. Because data were not normally distributed, a Kruskal-Wallis
test was followed by Dunn’s multiple comparison test to test statistical significance between condi-
tions. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Error bars represent means ± s.e.m.
Transmission electron microscopy
Tissue was processed for electron microscopy as previously described (Czopka and Lyons, 2011).
Briefly, 4 dpf larvae were anaesthetised with tricaine and chemically fixed with microwave stimulation
using a solution of 2% glutaraldehyde, 4% paraformaldehyde in 0.1 M sodium cacodylate buffer
(Agar Scientific, Essex, UK). Embryos subsequently underwent secondary fixation with microwave
stimulation in 2% osmium tetroxide in 0.1 M sodium cacodylate/imidazole (Agar Scientific) followed
by en bloc stain in saturated uranyl acetate (~8%, w/v, in water) (TAAB Laboratories Equipment Ltd.,
Berkshire, UK). Samples were then progressively dehydrated in a series of ethanol and acetone
washes before being embedded in Embed-812 resin (Electron Microscopy Sciences, Hatfield, PA).
Ultra-thin sections (70 nm thickness) were cut around somite 15 using a Reichert Jung Ultracut micro-
tome (Leica Microsystems, Wetzlar, Germany) and stained using uranyl acetate (TAAB Laboratories
Equipment Ltd.) and Sato lead stain (see (Czopka and Lyons, 2011) for detailed protocol). Stained
sections were imaged using a Jeol JEM-1400 Plus transmission electron microscope (JEOL USA, Inc.,
Peabody, MA) at 8600x magnification. Individual tiles were automatically aligned using the Photo-
Merge tool in Adobe Photoshop CC (Adobe Systems Inc., San Jose, CA) and quantified manually
using Fiji (ImageJ).
Statistical analyses
All data are expressed as mean ± SD, unless otherwise stated. Statistical tests were carried out using
GraphPad Prism 7. All automated analysis was performed by investigators blind to the experimental
treatment. For identification of hits from our primary screen, statistical significance was determined
by one-way ANOVA, with Dunnett’s multiple comparisons test performed on treatments within indi-
vidual experiments (from single clutches) compared to 1% DMSO controls. All other statistical analy-
sis was performed using one-way or two-way ANOVA with Dunnett’s or Tukey’s multiple
comparisons test where applicable or by two-tailed Student’s t-test as stated in the text. See
Supplementary file 3 for details of raw data and tests per individual experiments and their relevant
figure panel.
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Schenone M, Dančı́k V, Wagner BK, Clemons PA. 2013. Target identification and mechanism of action in
chemical biology and drug discovery. Nature Chemical Biology 9:232–240. DOI: https://doi.org/10.1038/
nchembio.1199, PMID: 23508189
Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S,
Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A. 2012. Fiji: an open-source
platform for biological-image analysis. Nature Methods 9:676–682. DOI: https://doi.org/10.1038/nmeth.2019,
PMID: 22743772
Schindelin J, Rueden CT, Hiner MC, Eliceiri KW. 2015. The ImageJ ecosystem: An open platform for biomedical
image analysis.Molecular Reproduction and Development 82:518–529. DOI: https://doi.org/10.1002/mrd.
22489, PMID: 26153368
Shin J, Park HC, Topczewska JM, Mawdsley DJ, Appel B. 2003. Neural cell fate analysis in zebrafish using olig2
BAC transgenics. Methods in Cell Science 25:7–14. DOI: https://doi.org/10.1023/B:MICS.0000006847.09037.
3a, PMID: 14739582
Sidorova-Darmos E, Wither RG, Shulyakova N, Fisher C, Ratnam M, Aarts M, Lilge L, Monnier PP, Eubanks JH.
2014. Differential expression of sirtuin family members in the developing, adult, and aged rat brain. Frontiers in
Aging Neuroscience 6:333. DOI: https://doi.org/10.3389/fnagi.2014.00333, PMID: 25566066
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